151 related articles for article (PubMed ID: 25304882)
1. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
Kubackova K; Bortlicek Z; Pavlik T; Melichar B; Linke Z; Pokorna P; Vyzula R; Prausova J; Buchler T;
Target Oncol; 2015 Sep; 10(3):385-92. PubMed ID: 25304882
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
3. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
4. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
6. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Wong MK; Yang H; Signorovitch JE; Wang X; Liu Z; Liu NS; Qi CZ; George DJ
Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
9. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
[TBL] [Abstract][Full Text] [Related]
10. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.
Poprach A; Bortlíček Z; Büchler T; Melichar B; Lakomý R; Vyzula R; Brabec P; Svoboda M; Dušek L; Gregor J
Med Oncol; 2012 Dec; 29(5):3314-20. PubMed ID: 22752571
[TBL] [Abstract][Full Text] [Related]
11. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Derbel Miled O; Dionne C; Terret C; Segura-Ferlay C; Flechon A; Neidhart EM; Negrier S; Droz JP
J Geriatr Oncol; 2013 Jul; 4(3):255-61. PubMed ID: 24070463
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
15. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
16. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kusuda Y; Harada K; Sakai I; Fujisawa M
Int J Clin Oncol; 2013 Feb; 18(1):81-6. PubMed ID: 22095244
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Ramaswamy A; Joshi A; Noronha V; Patil VM; Kothari R; Sahu A; Kannan RA; Sable N; Popat P; Menon S; Prabhash K
Clin Genitourin Cancer; 2017 Jun; 15(3):e345-e355. PubMed ID: 28077238
[TBL] [Abstract][Full Text] [Related]
19. Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
Biomed Res Int; 2017; 2017():9215930. PubMed ID: 28271073
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
